Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ACCESS Act back in House (and Senate)

Executive Summary

Sen. Sam Brownback, R-Kan., and Rep. Diane Watson, D-Calif., re-introduced the Access, Compassion, Care and Ethics for Seriously Ill Patients Act (ACCESS) May 21. The bill, initially introduced in 2005, would expand investigational treatment access for terminally ill patients who have exhausted other medical options (1"The Pink Sheet," Aug. 27, 2007, p. 9)

You may also be interested in...

Abigail Alliance Looks For Paths Forward After Court Blocks Drug Access Suit

After losing at the appeals court in its bid to overturn FDA's regulations on access to experimental therapies, the Abigail Alliance is considering several legal options. The group is preparing to ask the Supreme Court to consider the case, but if that bid fails, alternatives include congressional action and bringing another case in a different jurisdiction

European Medical Data Standards Offer Business Opportunities For Life Science Firms

The newly published EU IDMP guide on implementing ISO data standards for the identification of medicinal products will keep regulatory affairs professionals busy with compliance work while also creating new data-driven opportunities for life sciences companies. Remco Munnik shares the inside track from his work with the EU focus group that created the guide.

AZ’s ‘Long Shot’ COVID-19 Trial Of Diabetes Drug Farxiga Fails

The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts